Marshall Wace, LLP Solid Biosciences Inc. Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.69 - $2.46 $283,387 - $412,505	-167,685 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.38 - $3.77 $995,406 - $1.58 Million	-418,238 Reduced 71.38%	167,685 $401,000
Q2 2021 Aug 13, 2021	BUY	$3.49 - $5.51 $84,688 - $133,705	24,266 Added 4.32%	585,923 $2.14 Million
Q1 2021 May 17, 2021	BUY	$5.37 - $10.72 $3.02 Million - $6.02 Million	561,657 New	561,657 $3.11 Million
Q2 2019 Aug 14, 2019	SELL	$4.6 - $10.13 $321,139 - $707,205	-69,813 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$7.19 - $32.37 $348,060 - $1.57 Million	48,409 Added 226.17%	69,813 $642,000
Q4 2018 Feb 14, 2019	BUY	$21.32 - $46.34 $456,333 - $991,861	21,404 New	21,404 $574,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $24.3M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.